Rotator cuff calcific tendinopathy is the most common manifestation of hydroxyapatite deposition disease (HADD): deposition of calcium hydroxyapatite crystals within rotator cuff tendons. Peak age 30-60, female predominance, with an imaging prevalence of 3-20% of asymptomatic shoulders. It is distinct from degenerative rotator cuff tendinopathy - the deposit follows a defined biological cycle (Uhthoff lifecycle) and is usually self-limiting, but acute resorptive episodes can be severely painful and functionally disabling.
Deposits form preferentially within supraspinatus (over 50% of cases) followed by infraspinatus, then subscapularis, with teres minor involvement rare. Unlike degenerative tendinopathy this is a cell-mediated process rather than a wear-and-tear phenomenon.
The Uhthoff lifecycle has three phases:
The resorptive phase produces the acute severe presentation: the deposit becomes soft and paste-like under pressure within the tendon, triggering a genuine cell-mediated inflammatory response. This is why NSAIDs and corticosteroid injection are effective in resorptive calcific tendinopathy, unlike degenerative tendinopathy where anti-inflammatories have a limited role.
Risk factors include female sex, age 30-60, diabetes, thyroid disease, and metabolic syndrome.
The worst pain occurs during the resorptive phase - exactly when the deposit is dissolving. The acute severe flare is a good prognostic sign, not progressive disease. This counter-intuitive paradox is the most commonly tested fact about the condition.
Sign up to get full access to 10 topics of your choice, including all sections, clinical pearls, and exam tips.
Sign up free10 free topics included with your account. Full access from £24.17/month.
Sections included with full access